ClinicalTrials.gg
CompletedNCT01845584Updated Apr 12, 2017

Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy.

A Phase 2 interventional study of NPB-01 in Neuromyelitis Optica Spectrum Disorder, sponsored by Nihon Pharmaceutical Co., Ltd. Completed at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2017-04-12.

Sponsored by Nihon Pharmaceutical Co., Ltd · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Neuromyelitis Optica with a site in Japan — 2 open to participants now, 3 under way, 1 of them phase 3. Neuromyelitis Optica · Japan.

Enrollment
8th of 10
7 · median 72
Started
2013
the only one that year
Phase 2
Only one
of the 11
Registered
1st of 11
by date
Lead sponsor
1 of 11
Nihon Pharmaceutical Co., Ltd

Among the 11 studies in Neuromyelitis Optica with a site in Japan, this one is the 8th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2013, is the only one in phase 2, and was the 1st registered.

Neuromyelitis Optica

178 studies on the registry are indexed under Neuromyelitis Optica; 78 are open to participants now.

Browse Neuromyelitis Optica studies →

Open to participants now

2 of the 11 studies in Neuromyelitis Optica with a site in Japan are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 50 Neuromyelitis Optica studies recruiting now, 29 (58%) set no upper age limit and 16 (32%) stop at 75 or younger; 11 take children under 18; 9 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Neuromyelitis Optica with a site in Japan, or all of them as a file.
02

Study summary

Patients diagnosed with anti-aquaporin 4 antibody positive Neuromyelitis Optica spectrum disorder were confirmed based on diagnostic criteria. Patients who meet all inclusion criteria and do not conflict with the exclusion criteria will receive steroid plus therapy (1g/day for five consecutive days). Subsequently, patients who not provided adequate effect of therapy to steroids plus therapy will receive NPB-01 (intravenous immunoglobulin) 400mg/kg/day for five consecutive days. Patients evaluated Quantification of nerve and spinal cord impairment (QOSI) and the Expanded Disability Status Scale (EDSS)/ Functional Systems (FS) and anti-aquaporin 4 antibody et al.

As a safety endpoint, the safety of NPB-01 will be investigated the occurrence of adverse events by one year after the start of the study treatment.

03

Conditions studied

  • Neuromyelitis Optica Spectrum Disorder

Browse trials for

Keywords

  • IVIG in Neuromyelitis Optica spectrum disorder
  • Patients with Neuromyelitis Optica spectrum disorder
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients who become positive for anti-aquaporin 4 antibody or have becomed.
  2. Patients who have developed myelitis.
  3. Patients who run beyond greater than 30 days at least from last time in relapse.
  4. Patients who new neurological symptom or worsening neurological symptom or flared neurological symptom have sustained 24 hours at least not associated fever or infection.
  5. Patients who have an acute exacerbation at .
  6. Patients who need plus therapy(1g/day for five consecutive days).
  7. Patients who can start steroid plus therapy within 3 days after informed consent.
  8. Patients who be inadequate to effect to steroid plus therapy.
  9. Patients with greater than or equal to twenty years old at informed consent.

Exclusion criteria

Exclusion Criteria:

  1. Patients who have developed optic neuritis.
  2. Patients treated with intravenous immunoglobulin within 14 days before .
  3. Patients with at informed consent.
  4. Patients with history of shock or for NPB-01.
  5. Patients with IgA deficiency.
  6. Patients with impaired liver function.
  7. Patients with impaired renal function.
  8. Patients with cerebro- or cardiovascular disorders.
  9. Patients with high risk of thromboembolism.
  10. Patients with hemolytic/hemorrhagic anemia.
  11. Patients with decreased cardiac function.
  12. Patients with decreased .
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    NPB-01

    Intravenous immunoglobulin

    Drug: NPB-01

Interventions

  • DrugNPB-01

    Also known as: Intravenous immunoglobulin

06

What researchers measure

Primary outcomes

  1. Change from Baseline Quantification of nerve and spinal cord impairment (QOSI) at 29 days

    Time frame: 29 days

  2. Change from Baseline Expanded Disability Status Scale (EDSS)/ Functional Systems (FS) at 29 days

    Time frame: 29 days

  3. Change from Baseline anti-aquaporin 4 antibody at 29 days

    Time frame: 29 days

07

Study locations

1 site
  • Japan
    Osaka,, Japan
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2013 to primary completion in Aug 2015, 27 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2013
First posted
May 3, 2013
StartActual
May 2013
Primary completionActual
Aug 2015
CompletionActual
Aug 2015
Last update
Apr 12, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01845584
Lead sponsor
Nihon Pharmaceutical Co., Ltd
Responsible party
Sponsor
First posted
May 3, 2013
Start date
May 2013
Primary completion
Aug 2015
Completion
Aug 2015
Last update
Apr 12, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulins, Intravenous

Start the discussion